8 250

Cited 7 times in

Adjunctive Levetiracetam Treatment in Pediatric Lennox-Gastaut Syndrome

Authors
 Hyo Jeong Kim  ;  Shin Hye Kim  ;  Hoon-Chul Kang  ;  Joon Soo Lee  ;  Hee Jung Chung  ;  Heung Dong Kim 
Citation
 PEDIATRIC NEUROLOGY, Vol.51(4) : 527-531, 2014 
Journal Title
 PEDIATRIC NEUROLOGY 
ISSN
 0887-8994 
Issue Date
2014
MeSH
Adolescent ; Anticonvulsants/administration & dosage ; Anticonvulsants/adverse effects ; Anticonvulsants/pharmacology* ; Child ; Child, Preschool ; Drug Therapy, Combination ; Female ; Humans ; Infant ; Lennox Gastaut Syndrome/drug therapy* ; Male ; Piracetam/administration & dosage ; Piracetam/adverse effects ; Piracetam/analogs & derivatives* ; Piracetam/pharmacology ; Treatment Outcome
Keywords
Lennox-Gastaut syndrome ; child ; efficacy ; levetiracetam ; tolerability
Abstract
BACKGROUND: Our aim was to investigate the efficacy and tolerability of levetiracetam as an add-on treatment in pediatric patients with Lennox-Gastaut syndrome. METHODS: The study was an open-label, multicenter, observational clinical trial of levetiracetam as an add-on treatment in Lennox-Gastaut syndrome. Fifty-five patients aged 1.1-18.6 years (mean, 10.0 years) were enrolled. The study included a 4-8-week titration period and an 8-week maintenance period. The maintenance dose of levetiracetam was 20-80 mg/kg/day, according to its effectiveness and tolerability. The primary end point was reduction in seizure frequency, and related variables were also evaluated. RESULTS: Among 55 patents, 51 patients (92.7%) completed the study. Thirty-two patients (58.2%) experienced a more than 50% reduction in seizure frequency, and 15 patients (27.3%) became seizure free. A reduction in seizure frequency of more than 50% was observed in 21 of 36 patients (58.3%) with convulsive seizures, 7 of 12 patients (58.3%) with drop attacks, 2 of 4 patients (50.0%) with myoclonic seizures, and 2 of 3 patients (66.7%) with epileptic spasms. Overall, 34.5% of patients reported adverse events. None of the adverse events were life threatening, and the most common adverse event was hyperactivity (12.7%). CONCLUSIONS: This study suggests that levetiracetam is a safe and effective treatment in pediatric patients with Lennox-Gastaut syndrome.
Full Text
http://www.sciencedirect.com/science/article/pii/S0887899414003506
DOI
10.1016/j.pediatrneurol.2014.06.004
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Pediatrics (소아청소년과학교실) > 1. Journal Papers
Yonsei Authors
Kang, Hoon Chul(강훈철) ORCID logo https://orcid.org/0000-0002-3659-8847
Kim, Heung Dong(김흥동) ORCID logo https://orcid.org/0000-0002-8031-7336
Lee, Joon Soo(이준수) ORCID logo https://orcid.org/0000-0001-9036-9343
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/99739
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse